100 related articles for article (PubMed ID: 16123850)
1. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Yesilbursa D; Serdar A; Saltan Y; Serdar Z; Heper Y; Guclu S; Cordan J
Kardiol Pol; 2005 Jun; 62(6):526-30. PubMed ID: 16123850
[TBL] [Abstract][Full Text] [Related]
2. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Wu TJ; Ou HY; Chou CW; Hsiao SH; Lin CY; Kao PC
Ann Clin Lab Sci; 2007; 37(2):158-66. PubMed ID: 17522372
[TBL] [Abstract][Full Text] [Related]
3. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
[TBL] [Abstract][Full Text] [Related]
4. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients.
Coban E; Ozdogan M; Yazicioglu G; Sari R
Int J Clin Pract; 2005 Apr; 59(4):415-8. PubMed ID: 15853856
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
[TBL] [Abstract][Full Text] [Related]
6. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].
Márk L; Márki-Zay J; Orosz I; Kondacs A; Erdei F; Katona A
Orv Hetil; 2003 Apr; 144(16):765-8. PubMed ID: 12778627
[TBL] [Abstract][Full Text] [Related]
7. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Arca M; Natoli S; Micheletta F; Riggi S; Di Angelantonio E; Montali A; Antonini TM; Antonini R; Diczfalusy U; Iuliano L
Free Radic Biol Med; 2007 Mar; 42(5):698-705. PubMed ID: 17291993
[TBL] [Abstract][Full Text] [Related]
10. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Balogh Z; Seres I; Harangi M; Kovács P; Kakuk G; Paragh G
Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
[TBL] [Abstract][Full Text] [Related]
11. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
Okopień B; Cwalina Ł; Haberka M; Kowalski J; Zieliński M; Szwed Z; Kalina Z; Herman ZS
Pol Merkur Lekarski; 2002 Dec; 13(78):465-9. PubMed ID: 12666442
[TBL] [Abstract][Full Text] [Related]
12. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
13. [The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia].
Broncel M; Cieślak D; Koter-Michalak M; Duchnowicz P; Mackiewicz K; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2006 May; 20(119):547-50. PubMed ID: 16875159
[TBL] [Abstract][Full Text] [Related]
14. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
Rosenson RS
Obesity (Silver Spring); 2009 Mar; 17(3):504-9. PubMed ID: 19023279
[TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.
Kim CJ
J Cardiovasc Pharmacol; 2006 Jun; 47(6):758-63. PubMed ID: 16810076
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
17. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity.
Bełtowski J; Wójcicka G; Mydlarczyk M; Jamroz A
J Physiol Pharmacol; 2002 Sep; 53(3):463-75. PubMed ID: 12369742
[TBL] [Abstract][Full Text] [Related]
18. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
19. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Melenovsky V; Stulc T; Kozich V; Grauova B; Krijt J; Wichterle D; Haas T; Malik J; Hradec J; Ceska R
Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
